Innovation and pharmaceutical culture

Research & Development (R&D): Products of the future

Pharmaceutical innovation

Pierre Fabre pharmaceutical research focuses its energy and investments on three top-priority fields: oncology, dermatology and neuropsychiatry.

Dermo-cosmetics innovation

In an effort to provide the most comprehensive dermo-cosmetics solutions, our researchers work to identify new natural, biological and chemical substances and explore skin and hair mechanisms at the tissue, cellular and molecular levels.

Close to €200 MILLION

spent on R&D in 2015

16% OF
PHARMACEUTICAL TURNOVER

spent on pharmaceutical R&D in 2015

4% OF DERMO-COSMETICS TURNOVER

spent on dermo-cosmetics R&D in 2015

Biotechnologies: Cutting-edge expertise

2_1_biotechnologies.jpg

Biotechnologies encompass all the techniques of producing molecules from the natural world (animal, plant and microorganism cells). In the pharmaceutical field, this entails using the molecules generated to treat an organ or organism. Our company has specifically directed its efforts in this area toward designing, characterizing and producing anti-cancerous monoclonal antibodies. Monoclonal antibodies are compelling because of their highly targeted mode of action, effectiveness and increased tolerance to chemotherapy treatments. The Pierre Fabre Immunology Center of Saint-Julien (Haute-Savoie, France) is now internationally acclaimed for its expertise in this field.

The facility is also putting its skills to work for the Eau Thermale Avène brand. The I-Modulia active ingredient in the Avène XeraCalm A.D. line is produced at the antibodies biotechnology unit in a Good Manufacturing Practices environment identical to the one for anti-cancerous monoclonal antibodies.

Sterile Cosmetics: A new generation of care products

2_1_cosmetique_sterile_avene.jpg

In close cooperation with pharmacists and dermatologists, Pierre Fabre Laboratories develop skin care products that offer the highest level of quality, safety and efficacy. They rely on a scientific approach derived from the company’s pharmaceutical culture.

In the avant-garde spirit that defines them, Pierre Fabre Laboratories designed in the 1990s the first system that allows the manufacture of sterile single-dose, single-use care products for the most demanding types of skin. This patented system is marketed by the Avène brand under the name Extreme Tolerance System (ETS).

To make the sterile products available to as many users as possible and to promote treatment observance, a new research program has been set up. It began in 2009 with the launch of a new generation of care products: Sterile Cosmetics.

2_1_cosmetique_sterile_aderma.png

This new generation of care products, an assurance of absolute efficacy and safety for the most demanding types of skin (baby, hypersensitive, diseased and atopic skin), guarantees:

  • products with no preservatives or preservative-like substances, containing only absolutely essential components,
  • a unique manufacturing process developed by Pierre Fabre Laboratories' researchers and engineers: sterilization of infusion forms as a result of sterile bulk packaging, according to current standards in the pharmaceutical industry,
  • the sterility of the product throughout its use thanks to DEFI, the Device for Exclusive Formula Integrity, a patented packaging system. DEFI makes it possible to maintain the sterility of medicines, even after the tube is opened, with no risk of bacterial contamination during treatment.

Sterile Cosmetics, the only combination with three major innovations (formulation, packaging, manufacturing), meets the needs of dermatologists and pharmacists in their search for the safest and most effective solutions for the most demanding types of skin.

Sterile Cosmetics have been sold since 2009 by the Avène brand (Extreme Tolerance). They are also available as part of the A-Derma brand. They will gradually be expanded to all the products of Pierre Fabre Laboratories for the most demanding types of skin.